New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications

Anna Rosa Sannella, Angela Casini, Chiara Gabbiani, Luigi Messori, Anna Rita Bilia, Francesco Franco Vincieri, Giancarlo Majori, Carlo Severini

Research output: Contribution to journalArticlepeer-review

155 Scopus citations

Abstract

The clinically established gold-based antiarthritic drug auranofin (AF) manifests a pronounced reactivity toward thiol and selenol groups of proteins. In particular, AF behaves as a potent inhibitor of mammalian thioredoxin reductases causing severe intracellular oxidative stress. Given the high sensitivity of Plasmodium falciparum to oxidative stress, we thought that auranofin might act as an effective antimalarial agent. Thus, we report here new experimental results showing that auranofin and a few related gold complexes strongly inhibit P. falciparum growth in vitro. The observed antiplasmodial effects probably arise from direct inhibition of P. falciparum thioredoxin reductase. The above findings and the safe toxicity profile of auranofin warrant rapid evaluation of AF for malaria treatment in animal models.

Original languageEnglish
Pages (from-to)844-847
Number of pages4
JournalFEBS Letters
Volume582
Issue number6
DOIs
StatePublished - 19 Mar 2008
Externally publishedYes

Keywords

  • Gold drugs
  • Malaria
  • Plasmodium falciparum
  • Thioredoxin reductase

Fingerprint

Dive into the research topics of 'New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications'. Together they form a unique fingerprint.

Cite this